Lung Cancer Trials

LUN 567: An Open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer (TIGOS-LS)
OPEN FOR ENROLLMENT.

LUN630: A Randomized, Phase 3, Open-Label Study To Evaluate PF- 08046054/SGN-PDL1V VS DOCETAXEL In Adult Participants With Previously Treated Program Cell Death Ligan 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
OPEN FOR ENROLLMENT.

LUN644: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 >= 50%
Download Brochure

LUN643: An open-label, two arms, randomized, Phase 3 study evaluating the efficacy, safety of BMS‑986545-01 versus durvalumab in participants with locally advanced, unresectable Stage III NSCLC, who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (ROSETTA Lung-201)
Download Brochure

LUN629: A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer
Download Brochure

LUN638–A Phase 2 Randomized, Open label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination with Atezolizumab versus Standard of Care as First-Line Treatment in Subjects with Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC) 

LUN635–A Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer